CytomX Therapeutics, Inc.

NasdaqGS:CTMX Stock Report

Mkt Cap: US$166.5m

CytomX Therapeutics Past Performance

How has CytomX Therapeutics performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CTMX is currently unprofitable.

Growing Profit Margin: CTMX is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: CTMX is unprofitable, and losses have increased over the past 5 years at a rate of 8.2% per year.

Accelerating Growth: Unable to compare CTMX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CTMX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).

Return on Equity

High ROE: CTMX has a negative Return on Equity (-342.74%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies